Nanoparticles containing anti-inflammatory agents as chemotherapy adjuvants II: Role of plasma esterases in drug release

AAPS Journal

Volumn 11, Issue 1, 2009, Pages 120-122

  Lu, Xiuling ^a   Howard, Melissa D ^b   Talbert, Dominique R ^b   Rinehart, John J ^c   Potter, Philip M ^d   Jay, Michael ^a   Leggas, Markos ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b University of Kentucky   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Carboxylesterase; Dexamethasone palmitate; Esterolysis; Release; Solid lipid nanoparticle

Indexed keywords

DEXAMETHASONE; ESTERASE; SOLID LIPID NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG RELEASE; DRUG STABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PROTEIN FUNCTION; RAT;

ADJUVANTS, PHARMACEUTIC; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOTRANSFORMATION; CARBOXYLESTERASE; CULTURE MEDIA; DEXAMETHASONE; DRUG DELIVERY SYSTEMS; ESTERASES; ESTERS; HUMANS; HYDROLYSIS; MACROPHAGES; MICE; MICE, KNOCKOUT; MICE, NUDE; NANOPARTICLES; OPSONIN PROTEINS; PLASMA; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 65549144336     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-009-9086-3     Document Type: Article

References (12)

1. J. Rinehart, L. Keville, J. Neiddhart, L. Wong, L. DiNunno, P. Kinney, M. Aberle, L. Tadlock, and G. Cloud. Hematopoietic protection by dexamethasone or granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients treated with carboplatin and ifosfamide. Am. J. Clin. Oncol. 26: 448-458 (2003).
2. J. J. Rinehart, and L. R. Keville. Reduction in carboplatin hematopoietic toxicity in tumor bearing mice: Comparative mechanisms and effects of interleukin-1 beta and corticosteroids. Cancer Biother. Radiopharm. 12: 101-109 (1997).
3. H. Wang, M. Li, J. J. Rinehart, and R. Zhang. Dexamethasone as a chemoprotectant in cancer chemotherapy: Hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine. Cancer Chemother Pharmacol. 53: 459-467 (2004).
4. H. Wang, M. Li, J. J. Rinehart, and R. Zhang. Pretreatment with dexamethasone increases anti-tumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: In vivo activity, pharmacokinetics and clinical implications for cancer chemotherapy. Clin. Cancer Res. 10: 1633-1644 (2004).
5. M. Leggas, K. Kuo, F. Robert, G. Cloud, M. DeShazo, R. Zhang, M. Li, H. Wang, S. Davidson, and J. Rinehart. Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: Effect on chemotherapy toxicity and efficacy. Cancer Chemother Pharmacol. 63: 731-743. doi: 10.1007/s00280-008-0767-x.
6. X. Lu, M. D. Howard, M. Mazik, J. Eldridge, J.J. Rinehart, M. Jay, and M. Leggas. Nanoparticles containing anti-inflammatory agents as chemotherapy adjuvants: Optimization and characterization. AAPS J. 10: 133-140 (2008).
7. B. M. Liederer, and R. T. Borchardt. Stability of oxymethyl-modified coumarinic acid cyclic prodrugs of diastereomeric opioid peptides in biological media from various animal species including human. J. Pharm. Sci. 94: 2198-2206 (2005).
8. H. Pan, P. Kopeckova, J. Liu, D. Wang, S. C. Miller, and J. Kopecek. Stability in plasmas of various species of HPMA copolymer-PGE1 conjugates. Pharm. Res. 24: 2270-2280 (2007).
9. B. M. Liederer, and R. T. Borchardt. Enzymes involved in the bioconversion of ester-based prodrugs. J. Pharm. Sci. 95: 1177-1195 (2006).
10. H. Benameur, G. De Gand, R. Brasseur, J. P. Van Vooren, and F. J. Legros. Liposome-incorporated dexamethasone palmitate: Chemical and physical properties. Int. J. Pharmaceutics. 89: 157-167 (1993).
11. C. L. Morton, R. M. Wadkins, M. K. Danks, and P. M. Potter. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Cancer Res. 59: 1458-1463 (1999).
12. S. M. Moghimi, and J. Szebeni. Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res. 42: 463-478 (2003).